Cycurion, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cycurion, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $17.77M | Apr 17, 2025 |
| FY2024 | Dec 31, 2023 | $19.35M | Apr 17, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.13M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $17.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $19.35M | Apr 17, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.63M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.64M | Apr 17, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.67M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.23M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.10M) | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | ($700.9K) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($11.4K) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.41M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.42M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $326.4K | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | ($2.02M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($11.4K) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 17, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 17, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.21M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.32M | Apr 17, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.09M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.37M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.99M) | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.32M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($3.0K) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $448.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $12.8K | Apr 17, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.45M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $25.56M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $20.80M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $118.29M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $327.0K | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.18M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $15.55M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.24M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $313.4K | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.47M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.25M | Apr 17, 2025 |
| FY2024 | Dec 31, 2022 | $5.02M | Apr 17, 2025 |
| FY2023 | Dec 31, 2021 | $13.6K | Apr 26, 2024 |
| FY2022 | Apr 27, 2021 | $0 | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.59M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.59M | Apr 17, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.88M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.20M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.43M) | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.86M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($11.4K) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $38.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $607.9K | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | $809.5K | Apr 26, 2024 |
| FY2023 | Dec 31, 2021 | $3.9K | Apr 26, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 17, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 17, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.64M | Mar 31, 2026 |
| FY2025 | Oct 27, 2025 | 2.88M | Mar 31, 2026 |
| FY2025 | Oct 26, 2025 | 86.53M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 391,373 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 7.34M | Apr 17, 2025 |
| FY2023 | Dec 31, 2022 | 3.25M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | 2.88M | Mar 31, 2023 |